» Articles » PMID: 33504934

Serum Iron: a New Predictor of Adverse Outcomes Independently from Serum Hemoglobin Levels in Patients with Acute Decompensated Heart Failure

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jan 28
PMID 33504934
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Iron is an essential trace element in the body. However, in heart failure (HF), iron is only recognized as the cause of anemia. Actually, iron itself affects myocardial exercise tolerance and cardiac function via mitochondrial function. Therefore, it is necessary to clarify the pathological significance of iron in acute HF, irrespective of concomitant anemia. We investigated the impact of serum iron level at discharge on the prognosis of 615 patients emergently admitted with acute decompensated HF (ADHF). Patients were divided into two groups according to the median level of serum iron (62 µg/dL). The endpoint was the composite outcome, which included all-cause mortality and readmission for HF. During the mean follow-up period of 32.1 months, there were 333 events. Kaplan-Meier analysis showed that the incidence of the composite outcome was significantly higher in the Low iron group (P < 0.0001). In the multivariate analysis adjusted with factors including hemoglobin and ferritin levels, low serum iron was an independent predictor for the composite outcome (hazard ratio, 1.500; 95% confidence interval, 1.128-1.976; P = 0.0044). Low serum iron was an independent predictor of poor prognosis in ADHF, irrespective of hemoglobin or ferritin level, providing a new concept that iron may play a role in the pathophysiology of ADHF via non-hematopoietic roles.

Citing Articles

Transferrin Saturation, Serum Iron, and Ferritin in Heart Failure: Prognostic Significance and Proteomic Associations.

Gan S, Azzo J, Zhao L, Pourmussa B, Dib M, Salman O Circ Heart Fail. 2025; 18(2):e011728.

PMID: 39831311 PMC: 11835534. DOI: 10.1161/CIRCHEARTFAILURE.124.011728.


Association between serum transferrin saturation levels and heart failure in adults aged ≥40 years: a cross-sectional study based on NHANES (2017-2020.03).

Wang M, Zhang D, Jiang L, Ye M, Nie J, Yin J Front Endocrinol (Lausanne). 2024; 15:1419064.

PMID: 39280001 PMC: 11392747. DOI: 10.3389/fendo.2024.1419064.


Correlation between serum iron levels and pulmonary function: A cross-sectional analysis based on NHANES database 5319 cases.

Su L, Hu S, Wang S, Guo Q, Wei Y Medicine (Baltimore). 2023; 102(50):e36449.

PMID: 38115354 PMC: 10727669. DOI: 10.1097/MD.0000000000036449.


Markers of Iron Metabolism and Outcomes in Patients with Heart Failure: A Systematic Review.

Dhaliwal S, Kalogeropoulos A Int J Mol Sci. 2023; 24(6).

PMID: 36982717 PMC: 10059277. DOI: 10.3390/ijms24065645.


Biomarkers of Micronutrients and Phytonutrients and Their Application in Epidemiological Studies.

Zheng J, Wu F, Wang F, Cheng J, Zou H, Li Y Nutrients. 2023; 15(4).

PMID: 36839326 PMC: 9959711. DOI: 10.3390/nu15040970.


References
1.
Van Aelst L, Abraham M, Sadoune M, Lefebvre T, Manivet P, Logeart D . Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. Eur J Heart Fail. 2017; 19(8):1075-1076. DOI: 10.1002/ejhf.837. View

2.
Charles-Edwards G, Amaral N, Sleigh A, Ayis S, Catibog N, McDonagh T . Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency. Circulation. 2019; 139(21):2386-2398. DOI: 10.1161/CIRCULATIONAHA.118.038516. View

3.
Lam J, Schneider J, Quesenberry C, Corley D . Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency. Gastroenterology. 2016; 152(4):821-829.e1. DOI: 10.1053/j.gastro.2016.11.023. View

4.
Martens P, Nijst P, Verbrugge F, Smeets K, Dupont M, Mullens W . Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2017; 73(2):115-123. DOI: 10.1080/00015385.2017.1351239. View

5.
Murphy C, Oudit G . Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail. 2010; 16(11):888-900. DOI: 10.1016/j.cardfail.2010.05.009. View